Physician profile
Michael D Putman
NPI 1871848929
$1,691.73
in general payments reported to CMS, 2019-2025
14 companies · $406 in 2025
The $406 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38.89 · 2020: $102 · 2021: $101 · 2022: $283 · 2023: $400 · 2024: $361 · 2025: $406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,166.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $457.74 | 2019-2025 | |
| Abbvie INC. | $356.36 | 2022-2023 | |
| Amgen INC. | $185.63 | 2019-2025 | Tavneos, Krystexxa |
| Dexcom, INC. | $147.31 | 2021-2025 | Dexcom G6 Transmitter |
| Merit Medical Systems INC | $124.01 | 2025 | Esophyx |
| Ucb, INC. | $117.66 | 2024 | Bimzelx |
| Novo Nordisk INC | $98.15 | 2020-2023 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $61.64 | 2021-2022 | |
| Upsher-Smith Laboratories LLC | $38.43 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.18 | 2021-2023 | Synjardy, Jardiance |
| Astellas Pharma US INC | $24.50 | 2025 | Veozah |
| Biohaven Pharmaceuticals, INC. | $20.45 | 2020 | |
| Eisai INC. | $17.10 | 2020 | |
| Glaxosmithkline, LLC. | $12.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Putman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.